Drug Prices May Rise As Govt Plans Stricter Import Rules, Industry Voices Concern Over Proposed MIP Policy

Drug Prices May Rise As Govt Plans Stricter Import Rules, Industry Voices Concern Over Proposed MIP Policy

India may impose a Minimum Import Price on key drug ingredients to curb dependence on China, but the pharmaceutical industry fears this could raise production costs and lead to higher medicine prices. MSMEs may face significant disruption, and prices of government-procured medicines—especially amoxicillin-based—could rise by as much as 40 percent.

G R MukeshUpdated: Sunday, November 23, 2025, 10:43 AM IST
article-image
Industry Warns of Price Hike Amid Proposed Import Curbs. | File Photo

Mumbai: The pharmaceutical industry has recently expressed concern over a possible government policy that may introduce a Minimum Import Price (MIP) on certain essential drug ingredients. According to The Economic Times, industry players believe that imposing MIP on Active Pharmaceutical Ingredients (APIs) and finished drugs will increase production costs, ultimately pushing up medicine prices.

Why the Government May Impose MIP

As per the report, the proposed move aims to reduce India’s rising dependence on imported pharmaceutical raw materials—particularly from China. The government believes this dependence weakens the competitive capabilities of domestic firms. The report states that the Centre is considering MIP on key antibiotic raw materials such as Penicillin-G, 6APA, and amoxicillin.

Major Impact Likely on MSME Sector

The report highlights that thousands of MSME units in the pharmaceutical sector could be severely affected if MIP is imposed on these essential ingredients. Over 10,000 MSMEs may face closure, and more than 2 lakh jobs could be at risk. The government has earlier fixed an MIP of USD 111 per kg on ATS-8 until September 2026. Additionally, in October, an MIP of Rs 1,174 per kg was imposed on Sulphadiazine, applicable until September next year.

Self-Reliance Boost or New Challenge?

Experts cited by The Economic Times said the move appears aligned with the government’s Atmanirbhar Bharat (self-reliant India) mission. India continues to rely heavily on China for key pharmaceutical raw materials. In 2020, the government launched the PLI scheme to support domestic manufacturing of APIs. However, industry representatives argue that the PLI scheme was not intended to influence the prices of ingredients like 6APA or amoxicillin. Imposing MIP, they say, could send a signal that PLI-supported industries seek additional protection.

According to the report, if amoxicillin is also brought under MIP, the cost of medicines procured for government hospitals and public distribution channels could rise by up to 40 percent.

RECENT STORIES

Income Tax Refunds Still Stuck For Many, Here Is Why Notices Are Coming & What You Should Do?

Income Tax Refunds Still Stuck For Many, Here Is Why Notices Are Coming & What You Should Do?

Malpani Group's Heir Chose Love Over Generational Wealth: Says, 'These Kind Of Decisions Shape...

Malpani Group's Heir Chose Love Over Generational Wealth: Says, 'These Kind Of Decisions Shape...

Sensex & Nifty Face A Nervous Week Ahead, Q3 Results & Global Worries To Set Market Mood

Sensex & Nifty Face A Nervous Week Ahead, Q3 Results & Global Worries To Set Market Mood

New Income Tax Act To Start From April 1, Simpler Law To Replace 60-Year-Old Tax System

New Income Tax Act To Start From April 1, Simpler Law To Replace 60-Year-Old Tax System

NSE IPO Gets Closer To Reality, SEBI Likely To Give No-Objection Certificate By Month-End

NSE IPO Gets Closer To Reality, SEBI Likely To Give No-Objection Certificate By Month-End